Hybryte™疗法研究成果将于2026年美国皮肤淋巴瘤联盟年度研讨会公布_老虎社区_美港股上老虎

Hybryte™疗法研究成果将于2026年美国皮肤淋巴瘤联盟年度研讨会公布

美股速递03-23

Soligenix, Inc. 旗下Hybryte™疗法的临床研究成果，已确认将于2026年美国皮肤淋巴瘤联盟年度研讨会上正式发布。这一重要数据的公布，预示着该创新疗法在皮肤淋巴瘤治疗领域的最新进展将获得行业权威平台的集中展示。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1155823585?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-23 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155823585","market":"us","top_or_hot":-1,"title":"Hybryte™疗法研究成果将于2026年美国皮肤淋巴瘤联盟年度研讨会公布","media":"美股速递","content":"<p>Soligenix, Inc. 旗下Hybryte™疗法的临床研究成果，已确认将于2026年美国皮肤淋巴瘤联盟年度研讨会上正式发布。这一重要数据的公布，预示着该创新疗法在皮肤淋巴瘤治疗领域的最新进展将获得行业权威平台的集中展示。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hybryte™疗法研究成果将于2026年美国皮肤淋巴瘤联盟年度研讨会公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHybryte™疗法研究成果将于2026年美国皮肤淋巴瘤联盟年度研讨会公布\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-23 19:32 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Soligenix, Inc. 旗下Hybryte™疗法的临床研究成果，已确认将于2026年美国皮肤淋巴瘤联盟年度研讨会上正式发布。这一重要数据的公布，预示着该创新疗法在皮肤淋巴瘤治疗领域的最新进展将获得行业权威平台的集中展示。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1155823585","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155823585","pubTimestamp":1774265536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Soligenix, Inc. 旗下Hybryte™疗法的临床研究成果，已确认将于2026年美国皮肤淋巴瘤联盟年度研讨会上正式发布。这一重要数据的公布，预示着该创新疗法在皮肤淋巴瘤治疗领域的最新进展将获得行业权威平台的集中展示。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","SNGX":"Soligenix, Inc."},"translate_title":"Hybryte ™ Therapeutic research results to be announced at the 2026 American Skin Lymphoma Alliance Annual Symposium","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNGX":1},"content_text":"Soligenix, Inc. 旗下Hybryte™疗法的临床研究成果，已确认将于2026年美国皮肤淋巴瘤联盟年度研讨会上正式发布。这一重要数据的公布，预示着该创新疗法在皮肤淋巴瘤治疗领域的最新进展将获得行业权威平台的集中展示。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}